Cargando…

OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts

BACKGROUND: Bladder cancer lacks useful and robust prognostic markers to stratify patients at risk. Our study is to identify a robust prognostic marker for bladder cancer. METHODS: The transcriptome and clinical data of bladder cancer were downloaded from multiple databases. We searched for genes wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Jiaxing, Xu, Xiao, Li, Tianren, Yao, Jihang, Yu, Meng, Zhu, Yuyan, Sun, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634430/ https://www.ncbi.nlm.nih.gov/pubmed/34868901 http://dx.doi.org/10.3389/fonc.2021.650678

Ejemplares similares

OLFML2A Downregulation Inhibits Glioma Proliferation Through Suppression of Wnt/β-Catenin Signaling
por: Ma, Shize, et al.
Publicado: (2021)

Olfactomedin-like 2 A and B (OLFML2A and OLFML2B) expression profile in primates (human and baboon)
por: Pérez-Ibave, Diana Cristina, et al.
Publicado: (2016)

A robust 11-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts
por: Lin, Jiaxing, et al.
Publicado: (2020)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Lin, Jiaxing, et al.
Publicado: (2021)

Surfaceome CRISPR screen identifies OLFML3 as a rhinovirus-inducible IFN antagonist
por: Mei, Hong, et al.
Publicado: (2021)

Correction: Surfaceome CRISPR screen identifies OLFML3 as a rhinovirus-inducible IFN antagonist
por: Mei, Hong, et al.
Publicado: (2021)

OLFML2A Overexpression Predicts an Unfavorable Prognosis in Patients with AML
por: Lu, Xuan, et al.
Publicado: (2023)

Identification and Validation of the Prognostic Stemness Biomarkers in Bladder Cancer Bone Metastasis
por: Kang, Yao, et al.
Publicado: (2021)

miR-489-3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2
por: Sun, Dan, et al.
Publicado: (2020)

Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools
por: Liu, Jiaxin, et al.
Publicado: (2019)

Construction of a Macrophage Infiltration Regulatory Network and Related Prognostic Model of High-Grade Serous Ovarian Cancer
por: Chang, Hua, et al.
Publicado: (2021)

Correction to: Bioinformatic exploration of OLFML2B overexpression in gastric cancer base on multiple analyzing tools
por: Liu, Jiaxin, et al.
Publicado: (2019)

Genome-Wide Analyses of Prognostic and Therapeutic Alternative Splicing Signatures in Bladder Urothelial Carcinoma
por: Fan, Zhongru, et al.
Publicado: (2021)

OSblca: A Web Server for Investigating Prognostic Biomarkers of Bladder Cancer Patients
por: Zhang, Guosen, et al.
Publicado: (2019)

Novel Pyroptosis-Related Gene Signatures Identified as the Prognostic Biomarkers for Bladder Carcinoma
por: You, Jia, et al.
Publicado: (2022)

Robust Prognostic Subtyping of Muscle-Invasive Bladder Cancer Revealed by Deep Learning-Based Multi-Omics Data Integration
por: Zhang, Xiaolong, et al.
Publicado: (2021)

Comprehensive Analysis of a Competing Endogenous RNA Network Identifies Seven-lncRNA Signature as a Prognostic Biomarker for Melanoma
por: Liu, Nian, et al.
Publicado: (2019)

Pan-Cancer Analysis of OLFML2B Expression and Its Association With Prognosis and Immune Infiltration
por: Hu, Pengbo, et al.
Publicado: (2022)

LASSO-based screening for potential prognostic biomarkers associated with glioblastoma
por: Tian, Yin, et al.
Publicado: (2023)

Screening microRNAs as potential prognostic biomarkers for lung adenocarcinoma
por: Dai, Hongshuang, et al.
Publicado: (2023)

OLFML3 Expression is Decreased during Prenatal Muscle Development and Regulated by MicroRNA-155 in Pigs
por: Zhao, Shuanping, et al.
Publicado: (2012)

Identifying novel biomarkers associated with bladder cancer treatment outcomes
por: Castaneda, Peris R., et al.
Publicado: (2023)

Preoperative Serum Gamma-Glutamyltransferase as a Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer
por: Su, Shiqiang, et al.
Publicado: (2021)

Characterization of Cell Cycle-Related Competing Endogenous RNAs Using Robust Rank Aggregation as Prognostic Biomarker in Lung Adenocarcinoma
por: Yang, Yifei, et al.
Publicado: (2022)

Screening Protein Prognostic Biomarkers for Stomach Adenocarcinoma Based on The Cancer Proteome Atlas
por: Zheng, Guo-Liang, et al.
Publicado: (2022)

A metabolic reprogramming-related prognostic risk model for clear cell renal cell carcinoma: From construction to preliminary application
por: Zhang, Qian, et al.
Publicado: (2022)

GeneChip expression profiling identified OLFML2A as a potential therapeutic target in TNBC cells
por: Gao, Xiufei, et al.
Publicado: (2022)

Transcriptome-Wide Map of N(6)-Methyladenosine Methylome Profiling in Human Bladder Cancer
por: Li, Aolin, et al.
Publicado: (2021)

The Ferroptosis-Related Noncoding RNA Signature as a Novel Prognostic Biomarker in the Tumor Microenvironment, Immunotherapy, and Drug Screening of Gastric Adenocarcinoma
por: Chen, Xinming, et al.
Publicado: (2021)

Editorial: Identifying novel biomarkers in bladder cancer
por: Ecke, Thorsten H., et al.
Publicado: (2023)

Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer
por: Cheng, Xiangming, et al.
Publicado: (2018)

CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays
por: Yan, Xin, et al.
Publicado: (2021)

Screening of miRNAs as Prognostic Biomarkers for Colon Adenocarcinoma and Biological Function Analysis of Their Target Genes
por: Zheng, Guoliang, et al.
Publicado: (2021)

Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer
por: Zheng, Zongtai, et al.
Publicado: (2020)

A deep learning model for drug screening and evaluation in bladder cancer organoids
por: Zhang, Shudi, et al.
Publicado: (2023)

CircRNAs: Emerging Bladder Cancer Biomarkers and Targets
por: Liang, Zhaofeng, et al.
Publicado: (2021)

Robust Glycogene-Based Prognostic Signature for Proficient Mismatch Repair Colorectal Adenocarcinoma
por: Li, Yixi, et al.
Publicado: (2021)

Identification of therapeutic targets and prognostic biomarkers in cholangiocarcinoma via WGCNA
por: Xu, Lei, et al.
Publicado: (2022)

Seven DNA Methylation Biomarker Prediction Models for Monitoring the Malignant Progression From Advanced Adenoma to Colorectal Cancer
por: Wang, Wei, et al.
Publicado: (2022)

M2 Macrophage Co-Expression Factors Correlate With Immune Phenotype and Predict Prognosis of Bladder Cancer
por: Wang, Yutao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sta2u488h91a4ih32os5rh9vjf